Author: Adney, Danielle R.; Wang, Lingshu; van Doremalen, Neeltje; Shi, Wei; Zhang, Yi; Kong, Wing-Pui; Miller, Megan R.; Bushmaker, Trenton; Scott, Dana; de Wit, Emmie; Modjarrad, Kayvon; Petrovsky, Nikolai; Graham, Barney S.; Bowen, Richard A.; Munster, Vincent J.
Title: Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas Cord-id: r8n0x6s9 Document date: 2019_3_2
ID: r8n0x6s9
Snippet: MERS-CoV is present in dromedary camels throughout the Middle East and Africa. Dromedary camels are the primary zoonotic reservoir for human infections. Interruption of the zoonotic transmission chain from camels to humans, therefore, may be an effective strategy to control the ongoing MERS-CoV outbreak. Here we show that vaccination with an adjuvanted MERS-CoV Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and results in reduced and delayed viral shedd
Document: MERS-CoV is present in dromedary camels throughout the Middle East and Africa. Dromedary camels are the primary zoonotic reservoir for human infections. Interruption of the zoonotic transmission chain from camels to humans, therefore, may be an effective strategy to control the ongoing MERS-CoV outbreak. Here we show that vaccination with an adjuvanted MERS-CoV Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and results in reduced and delayed viral shedding in the upper airways of dromedary camels. Protection in alpaca correlates with high serum neutralizing antibody titers. Lower titers of serum neutralizing antibodies correlate with delayed and significantly reduced shedding in the nasal turbinates of dromedary camels. Together, these data indicate that induction of robust neutralizing humoral immune responses by vaccination of naïve animals reduces shedding that potentially could diminish the risk of zoonotic transmission.
Search related documents:
Co phrase search for related documents- activity level and adjuvant system: 1
- activity level and low amount: 1
- activity level and low prevalence: 1, 2, 3
- acute rhinitis and adjuvant system: 1
- acute rhinitis and lung trachea: 1
- ad libitum and additional control: 1
- ad libitum and lysis buffer: 1
- additional control and low prevalence: 1
- additional control and lung trachea: 1
- adjuvant system and lymph node: 1
Co phrase search for related documents, hyperlinks ordered by date